Fortrea Strengthens Leadership With Appointment Of Scott Dove As President Of Clinical Pharmacology Services, As Oren Cohen Focuses On Chief Medical Officer Role

Fortrea, a global contract research organisation (CRO), has announced key updates to its executive leadership team. Dr Oren Cohen, who previously held dual roles as Chief Medical Officer (CMO) and President of Clinical Pharmacology Services (CPS), will now focus exclusively on his CMO responsibilities. In this dedicated role, he will oversee medical strategy, scientific leadership, and ethics and governance across Fortrea’s full portfolio.

At the same time, Fortrea has appointed Dr Scott Dove as President of Clinical Pharmacology Services. He will lead the company’s early clinical development solutions and oversee its global network of clinical research units. Both Dr Cohen and Dr. Dove will serve on Fortrea’s Executive Committee.

Dr. Cohen brings more than two decades of experience in drug development and executive medical leadership within the pharmaceutical industry. Prior to joining Fortrea, he served as Chief Medical Officer and Head of Clinical Pharmacology Services at Labcorp Drug Development. Earlier in his career, he was CMO at Viamet Pharmaceuticals and held several senior medical and operational leadership roles at Quintiles, now part of IQVIA.

“The addition of Scott to the Fortrea team while Oren becomes fully dedicated to the medical and scientific aspects of development is a win for clients,” said Anshul Thakral, CEO. “Working closely with our business leaders across all phases of clinical development, Oren will deepen his relationships with clients. He’s engaging earlier in scientific dialogue and collaborating closely with our physicians and therapeutic leaders to help address complex development challenges, all while upholding the highest standards of scientific integrity and patient safety. Scott is making a fast start with our Clinical Pharmacology team and is getting a first-hand view of our world-class clinics. He combines a strong technical background in clinical development and operations with a successful track record of leadership in building and leading global organizations, and I’m looking forward to his insights on how we further strengthen our offering.”

He earned his MD from Duke University and completed his internship and residency at New York Hospital-Cornell Medical Center. He later completed a fellowship in Infectious Diseases at the National Institute of Allergy and Infectious Diseases, where he remained as a Principal Investigator and served as Assistant Director for Medical Affairs. Dr. Cohen is currently a Consulting Professor of Medicine at Duke University Medical Center, a member of the Board of Visitors for Duke University School of Medicine, and a Fellow of the Infectious Diseases Society of America.

Dr. Scott Dove joins Fortrea with more than 25 years of experience across pharmaceutical, biotechnology, and CRO organisations. Most recently, he served as an advisor to several companies, including Fortrea. Previously, he was Chief Operating Officer at Aravive, where he led R&D operations for the clinical-stage oncology company. He also spent more than a decade at PPD, leading early development services, and held additional leadership roles at Allergan and Furiex Pharmaceuticals. Dr. Dove earned his PhD from Texas A&M Health Science Centre and holds a Bachelor of Science in Biochemistry from Texas A&M University.